Denver News Updates

Cervical Dystonia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AbbVie, Akorn, Eisai, Galderma, Ipsen, Lannett, Medytox, Merz Pharma, Revance

 Breaking News
  • No posts were found

Cervical Dystonia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AbbVie, Akorn, Eisai, Galderma, Ipsen, Lannett, Medytox, Merz Pharma, Revance

May 25
19:20 2023
Cervical Dystonia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AbbVie, Akorn, Eisai, Galderma, Ipsen, Lannett, Medytox, Merz Pharma, Revance
Delveinsight Business Research LLP
“Cervical Dystonia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cervical Dystonia Market.

The Cervical Dystonia Pipeline report embraces in-depth commercial, regulatory, and Cervical Dystonia clinical trail assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Cervical Dystonia drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Cervical Dystonia Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Cervical Dystonia treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Cervical Dystonia therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Cervical Dystonia companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Cervical Dystonia drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cervical Dystonia therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Cervical Dystonia Pipeline Analysis

Analysis of Emerging Cervical Dystonia Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Cervical Dystonia Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Cervical Dystonia Therapeutics Landscape

Currently, the Cervical Dystonia (CD) treatment is symptomatic and is intended to relieve spasms, pain, and disturbed postures or functions. Available interventions for Cervical Dystonia include oral medications, intramuscular injections, intrathecal infusions, surgical procedures, and physical/rehabilitation therapies. These treatments may be used alone or in combination. In addition, physical therapy may provide a helpful complement to medical treatment.

To further improve the treatment scenario, key players such as Revance Therapeutics, Addex Therapeutics, Medytox, and others are developing effective therapies for Cervical Dystonia. Extensive research and development activities of pharmaceutical companies for developing therapies for Cervical Dystonia will significantly impact the market outlook and the treatment scenario in the upcoming years. 

Cervical Dystonia Companies Actively Working in the Therapeutic Market Include:

  • AbbVie Inc.

  • Akorn Inc.

  • Eisai Co. Ltd.

  • Galderma SA

  • Ipsen Pharma

  • Lannett Co. Inc.

  • Medytox Inc.

  • Merz Pharma GmbH and Co. KGaA

  • Revance Therapeutics Inc.

  • Supernus Pharmaceuticals Inc.

And Many Others

Emerging and Marketed Cervical Dystonia Drugs Covered in the Report Include:

  • RT002: Revance Therapeutics

  • Dipraglurant-ER: Addex Therapeutics

  • ABP-450: AEON Biopharma

  • Onabotulinumtoxin A: BOTOX, Allergan Inc.

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Cervical Dystonia Companies Working in the Market:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Cervical Dystonia Treatment Patterns

4. Cervical Dystonia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cervical Dystonia Late Stage Products (Phase-III)

7. Cervical Dystonia Mid-Stage Products (Phase-II)

8. Cervical Dystonia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cervical Dystonia Discontinued Products

13. Cervical Dystonia Product Profiles

14. Major Cervical Dystonia Companies in the Market

15. Key Products in the Cervical Dystonia Therapeutics Segment

16. Dormant and Discontinued Products

17. Cervical Dystonia Unmet Needs

18. Cervical Dystonia Future Perspectives

19. Cervical Dystonia Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Orthostatic Hypotension Market

“Orthostatic Hypotension Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Orthostatic Hypotension market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Orthostatic Hypotension market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States